[根据欧洲抗风湿病联盟（EULAR 2016）的建议，针对痛风的发作、病程及合并症情况采取合理的治疗方法]

[A rationally grounded approach to treating gout with regard to its onset and course and the presence of comorbidity according to the European League against Rheumatism (EULAR 2016) recommendations].

作者信息

Tsurko V V, Gromova M A

机构信息

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia.

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia.

出版信息

Ter Arkh. 2017;89(12. Vyp. 2):233-237. doi: 10.17116/terarkh20178912233-237.

DOI:10.17116/terarkh20178912233-237

PMID:29488486

Abstract

The review analyzes in detail the management of gout, which takes into account its onset and course and the presence of comorbidity. Emphasis is placed on drug and non-drug treatments and urate-lowering therapy in patients with kidney dysfunction. Along with allopurinol, the urate-lowering drug febuxostat is first recommended in Russia. The purpose of this review is to notify physicians of the possibility of achieving the target uric acid levels when treating gout with hyperuricemia.

摘要

该综述详细分析了痛风的管理，其中考虑了痛风的发病情况、病程以及合并症的存在。重点在于药物和非药物治疗以及肾功能不全患者的降尿酸治疗。在俄罗斯，除别嘌醇外，降尿酸药物非布司他也首次被推荐使用。本综述的目的是告知医生，在治疗高尿酸血症痛风时达到目标尿酸水平的可能性。